ID: MRFR/LS/0821-HCR | 95 Pages | Author: Rahul Gotadki | March 2024
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL BIOSIMILARS MARKET, BY PRODUCT
6.1. Overview
6.2. Recombinant Non-Glycosylated Proteins
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.1. Human Growth Hormone (RHGH)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.2. Granulocyte Colony-Stimulating Factor (Filgrastim)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.3. Insulin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.2.4. Interferons
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3. Recombinant Glycosylated Proteins
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.1. Erythropoietin (EPO)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.2. Monoclonal Antibodies (MABS)
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.3.3. Follitropin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4. Recombinant Peptides
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.1. Glucagon
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
6.4.2. Calcitonin
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7. GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS
7.1. Overview
7.2. Oncology
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.3. Chronic Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.4. Autoimmune Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.5. Blood Disorders
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.6. Growth Hormone Deficiency
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.7. Infectious Diseases
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
7.8. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8. GLOBAL BIOSIMILARS MARKET, BY END USER
8.1. Overview
8.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.3. Research Institutes
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
8.4. Others
Market Estimates & Forecast, by Region, 2020-2027
Market Estimates & Forecast, by Country, 2020-2027
9. GLOBAL BIOSIMILARS MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Biosimilars Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Biosimilars Market
10.7. Key developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2020
10.8.2. Major Players R&D Expenditure 2020
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. Pfizer
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Sandoz International
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Teva Pharmaceuticals
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Amgen, Inc.
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Biocon
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Dr. Reddy’s Laboratories
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Celltrion
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Samsung Biologics
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Eli Lily & Company
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Hospira Inc.
11.10.1. Company Overview
11.10.2. Product Overview
11.10.3. Financial Overview
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Actavis, Inc.
11.12. Cipla Ltd
11.13. Stada Arzneimittel Ag
11.14. Mylan, Inc.
11.15. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL BIOSIMILARS MARKET SYNOPSIS, 2020-2027
TABLE 2 GLOBAL BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL BIOSIMILARS MARKET, BY REGION, 2020-2027 (USD MILLION)
TABLE 7 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 8 NORTH AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 9 NORTH AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 10 US: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 11 US: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 12 US: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 13 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 14 CANADA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 15 CANADA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 16 LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 17 LATIN AMERICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 18 LATIN AMERICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 19 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 20 EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 21 EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 22 WESTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 23 WESTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 24 WESTERN EUROPE: BIOSIMILARS MARKET, BY END USERS E, 2020-2027 (USD MILLION)
TABLE 25 EASTERN EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 26 EASTERN EUROPE: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 27 EASTERN EUROPE: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 28 ASIA-PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 29 ASIA-PACIFIC: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 30 ASIA-PACIFIC: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET, BY END USERS, 2020-2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BIOSIMILARS MARKET
FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BIOSIMILARS MARKET
FIGURE 4 GLOBAL BIOSIMILARS MARKET SHARE, BY PRODUCT, 2020 (%)
FIGURE 5 GLOBAL BIOSIMILARS MARKET SHARE, BY APPLICATIONS, 2020 (%)
FIGURE 6 GLOBAL BIOSIMILARS MARKET SHARE, BY END USERS, 2020 (%)
FIGURE 7 GLOBAL BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 AMERICAS: BIOSIMILARS MARKET SHAR,E BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 EUROPE: BIOSIMILARS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 WESTERN EUROPE: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 ASIA-PACIFIC: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 MIDDLE EAST & AFRICA: BIOSIMILARS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 GLOBAL BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 15 PFIZER: KEY FINANCIALS
FIGURE 16 PFIZER: SEGMENTAL REVENUE
FIGURE 17 PFIZER: REGIONAL REVENUE
FIGURE 18 SANDOZ INTERNATIONAL: KEY FINANCIALS
FIGURE 19 SANDOZ INTERNATIONAL: SEGMENTAL REVENUE
FIGURE 20 SANDOZ INTERNATIONAL: REGIONAL REVENUE
FIGURE 21 AMGEN, INC.: KEY FINANCIALS
FIGURE 22 AMGEN, INC.: SEGMENTAL REVENUE
FIGURE 23 AMGEN, INC.: REGIONAL REVENUE
FIGURE 24 TEVA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 25 TEVA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 26 TEVA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 27 BIOCON: KEY FINANCIALS
FIGURE 28 BIOCON: SEGMENTAL REVENUE
FIGURE 29 BIOCON: REGIONAL REVENUE
FIGURE 30 DR. REDDY’S LABORATORIES: KEY FINANCIALS
FIGURE 31 DR. REDDY’S LABORATORIES: SEGMENTAL REVENUE
FIGURE 32 DR. REDDY’S LABORATORIES: REGIONAL REVENUE
FIGURE 33 CELLTRION: KEY FINANCIALS
FIGURE 34 CELLTRION: SEGMENTAL REVENUE
FIGURE 35 CELLTRION: REGIONAL REVENUE
FIGURE 36 SAMSUNG BIOLOGICS: KEY FINANCIALS
FIGURE 37 SAMSUNG BIOLOGICS: SEGMENTAL REVENUE
FIGURE 38 SAMSUNG BIOLOGICS: REGIONAL REVENUE
FIGURE 39 ELI LILY & COMPANY: KEY FINANCIALS
FIGURE 40 ELI LILY & COMPANY: SEGMENTAL REVENUE
FIGURE 41 ELI LILY & COMPANY: REGIONAL REVENUE
FIGURE 42 HOSPIRA INC.: KEY FINANCIALS
FIGURE 43 HOSPIRA INC.: SEGMENTAL REVENUE
FIGURE 44 HOSPIRA INC.: REGIONAL REVENUE
FIGURE 45 ACTAVIS, INC.: KEY FINANCIALS
FIGURE 46 ACTAVIS, INC.: SEGMENTAL REVENUE
FIGURE 47 ACTAVIS, INC.: REGIONAL REVENUE
FIGURE 48 CIPLA LTD.: KEY FINANCIALS
FIGURE 49 CIPLA LTD.: SEGMENTAL REVENUE
FIGURE 50 CIPLA LTD.: REGIONAL REVENUE
FIGURE 51 STADA ARZNEIMITTEL AG: KEY FINANCIALS
FIGURE 52 STADA ARZNEIMITTEL AG: SEGMENTAL REVENUE
FIGURE 53 STADA ARZNEIMITTEL AG: REGIONAL REVENUE
FIGURE 54 MYLAN, INC.: KEY FINANCIALS
FIGURE 55 MYLAN, INC.: SEGMENTAL REVENUE
FIGURE 56 MYLAN, INC.: REGIONAL REVENUE
Market Segmentation for Biosimilars Market
Biosimilars Product Outlook (USD Billion, 2018-2030)
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Biosimilars Applications Outlook (USD Billion, 2018-2030)
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Biosimilars End User Outlook (USD Billion, 2018-2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Biosimilars Regional Outlook (USD Billion, 2018-2030)
North America Outlook (USD Billion, 2018-2030)
North America Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
North America Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
North America Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
US Outlook (USD Billion, 2018-2030)
US Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
US Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
US Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Canada Outlook (USD Billion, 2018-2030)
Canada Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Canada Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Canada Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe Outlook (USD Billion, 2018-2030)
Europe Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Europe Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Europe Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Germany Outlook (USD Billion, 2018-2030)
Germany Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Germany Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Germany Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
France Outlook (USD Billion, 2018-2030)
France Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
France Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
France Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
UK Outlook (USD Billion, 2018-2030)
UK Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
UK Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
UK Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Italy Outlook (USD Billion, 2018-2030)
Italy Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Italy Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Italy Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Spain Outlook (USD Billion, 2018-2030)
Spain Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Spain Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Spain Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest Of Europe Outlook (USD Billion, 2018-2030)
Rest Of Europe Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Rest of Europe Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Rest of Europe Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia-Pacific Outlook (USD Billion, 2018-2030)
Asia-Pacific Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Asia-Pacific Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Asia-Pacific Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
China Outlook (USD Billion, 2018-2030)
China Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
China Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
China Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Japan Outlook (USD Billion, 2018-2030)
Japan Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Japan Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Japan Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
India Outlook (USD Billion, 2018-2030)
India Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
India Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
India Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Australia Outlook (USD Billion, 2018-2030)
Australia Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Australia Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Australia Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
South Korea Outlook (USD Billion, 2018-2030)
South Korea Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
South Korea Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
South Korea Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
Rest of Asia-Pacific Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Rest of Asia-Pacific Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Rest of Asia-Pacific Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of the World Outlook (USD Billion, 2018-2030)
Rest of the World Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Rest of the World Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Rest of the World Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East Outlook (USD Billion, 2018-2030)
Middle East Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Middle East Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Middle East Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa Outlook (USD Billion, 2018-2030)
Africa Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Africa Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Africa Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America Outlook (USD Billion, 2018-2030)
Latin America Biosimilars by Product
Recombinant Non-Glycosylated Proteins
Human Growth Hormone (RHGH)
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferons
Recombinant Glycosylated Proteins
Erythropoietin (EPO)
Monoclonal Antibodies (MABS)
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Latin America Biosimilars by ApplicationsÂ
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Others
Latin America Biosimilars by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Research Methodology on Biosimilars Market
Introduction
The advancement in biotechnology and the increasing number of applications of biologics and biosimilars in therapeutics and diagnostics has created a need to understand the factors driving the global biosimilars market. Biosimilars are drug products similar to the originator biologic product but not an exact copy of it, developed and manufactured using recombinant DNA technology for commercial use in the marketplace. The Market Research Future (MRFR) report studies this market in detail with a focus on several factors such as market growth drivers, challenges, regional markets, and competitive landscape.
Research Objectives
The objectives of this comprehensive research are to:
Research Methodology
Research design and approach
The study is based on the analysis of both secondary and primary data sources. Secondary data related to the biosimilars market is collected from various published sources, such as annual reports, news articles and press releases, patent applications, and recognised sources from industry publications. Primary data is collected through interviews with experts and leading industry professionals, as well as through surveys for customer and consumer treatment data about biosimilars. Additionally, data is also collected through interviews and surveys with clinicians, regulatory bodies, resellers, and distributors. The research team also conducts detailed analyses of collected data to conclude.
Primary Research
Primary research methods are used to uncover the pieces of information that cannot be determined through secondary data. Primary research involves interviewing clinical experts, medical and market researchers, key industry opinion leaders, and regulatory bodies, and holds immense importance in the market study. Through primary research, the team strives to understand and accurately reflect and assess the state of the biosimilars market.
Secondary Research
Secondary sources, such as Annual Reports, Medical Journals, and Economic Forecasts, are referred to analyse the industry trends and to enable a comprehensive understanding of the biosimilars market. All of these sources are constantly monitored to help verify, update, and extrapolate data, to offer accurate and up-to-date market intelligence. The team also features industry experts, who constantly monitor and analyze the pharmaceuticals industry in various regions.
Market Segmentation
The market of biosimilars is segmented based on type into monoclonal antibodies and other biosimilars (recombinant proteins, hormones, interferons, and insulin). Other biosimilars are further segmented into epoetin alfa, filgrastim, granulocyte growth factor, and interferon among others. Based on therapeutic areas, the market is segmented into oncology, immunology, a blood disorder, cardiovascular, endocrinology and other therapeutic areas. Based on end users, the market is segmented into hospitals, speciality clinics, retail pharmacies and online pharmacies.
Data Triangulation
Data triangulation is used to validate the results of data collection and the uncertainty associated with each estimate. Different combinations of data from multiple sources are used to develop and verify the market estimates. Also, the weighted average of the original sizes and the expected growth from the same sources are used to corroborate the market estimations.
Conclusion
This comprehensive research methodology provides systematic and thorough information about the current biosimilar market and the forces shaping it. It covers all the major facets of the global biosimilars market and helps to create an in-depth understanding of the market. The research reveals that the biosimilars market is expected to grow at a steady pace during the forecast period of 2023-2030. Factors such as increasing research & development activities, regulatory changes, technological advancements etc. are expected to drive the biosimilars market growth in the coming years.